

BC Cancer news and updates from across the province for Systemic Therapy teams

Provincial Systemic Therapy Drug Programs Under Consideration



Adverse Events

Treatment Programs	Indication (Refer to protocol for more details)	Associated Adverse Events
Regorafenib	Treatment of patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib	Possible adverse events (of any grade): <ul style="list-style-type: none"> • Hand-foot skin reaction* • Hypertension • Fatigue • Diarrhea • Mucositis • Anorexia • Hyperbilirubinemia • Nausea

* Hand-foot skin reaction is a dermatologic toxicity associated with burning, numbness and tingling to palms and soles as well as areas of friction or pressure. It can develop into ulcers and blisters causing severe discomfort and inability to perform activities of daily living.

Treatment Regimens: Dosing and Administration Schedules

1. Regorafenib: Advanced HCC

Dosing and Schedule:

- **Oral Regorafenib** 160 mg* once daily for 21 days, followed by 7-day rest (each cycle consist of 28 days) until disease progression.
- Regorafenib must be taken at the same time each day after a light, low-fat, low-calorie meal.

*May start with 120 mg daily and escalate to 160 mg daily if tolerated (dosing ranges from 80 mg – 160 mg).

Website Resources and Contact Information

CONTACT INFORMATION	EMAIL
To subscribe to Education Bulletin or to update contact information, please contact:	
Provincial Systemic Therapy Program	ProvincialSystemicOffice@bccancer.bc.ca